Heart:无症状性主动脉瓣狭窄患者体内Galectin-3的价值和影响因素

2016-02-22 QQduhp 译 MedSci原创

目的对于患有无症状严重主动脉瓣狭窄(AS)的患者而言,是否出现心肌纤维化可作为一个影响患者是否手术的预测因子。使用核磁共振检测可得出结论,但近年来较少使用,且使用生物标记物替代并十分可取。 研究人员分析了galectin-3(与心肌纤维化有关的生物标志物)的决定因素和预后价值。 方式2006-2013年参与两项正在进行的研究(COFRASA/GENERAC)且至少患有轻度AS的患者参与研究,旨在评

目的:对于患有无症状严重主动脉瓣狭窄(AS)的患者而言,是否出现心肌纤维化可作为一个影响患者是否手术的预测因子。使用核磁共振检测可得出结论,但近年来较少使用,且使用生物标记物替代并十分可取。 研究人员分析了galectin-3(与心肌纤维化有关的生物标志物)的决定因素和预后价值。 


方式:两项在2006-2013年间进行的研究(COFRASA/GENERAC),参与者均为至少患有轻度AS的患者,研究旨在评估这种生物标记物对AS发生和发展的影响。

结果:一共有583名患者参与研究,平均galectin-3水平为14.3±5.6ng/mL。结果表明,galectin-3水平与患者机体健康状况(p=0.55)和AS严重性(p=0.58)无关。其他影响galectin-3的因素分别为年龄(p=0.0008)、 女性(p=0.04)、高血压(p=0.002)、糖尿病(p=0.02)、左心室射血分数降低(p=0.01)、心脏舒张功能不全(E/e′,p=0.02) 、肌酐清除率(p<0.0001)。在330名无症状患者中,研究人员通过进行单变量分析发现,galectin-3不是预测因子(p=0.73),在调整年龄、性别、心率、肌酐清除率和AS严重程度等因素后也并非预测因子(p=0.66)。 

结论:通过对众多AS患者调查后,研究人员发现,galectin-3水平与患者机体健康状况和AS严重性无关。影响galectin-3的因素主要为年龄、高血压、肾功能。Galectin-3也并不能预测AS相关疾病的发生和发展,研究人员表示仍需进行更进一步的探索。 

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
    2016-03-25 1ddc978cm67(暂无匿称)

    谢谢,学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
    2016-02-24 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1774444, encodeId=54e41e7444445, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Apr 21 10:31:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=73674, encodeId=da3ce367461, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 25 05:54:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332384, encodeId=637d1332384b1, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356056, encodeId=f3df135605629, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415031, encodeId=5ef3141503193, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465526, encodeId=dca91465526cb, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484944, encodeId=61a9148494439, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562355, encodeId=82ff15623559f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Feb 24 02:31:00 CST 2016, time=2016-02-24, status=1, ipAttribution=)]
    2016-02-24 slcumt

相关资讯

心脏彩超及解剖对比

心脏彩超正常值 内径(mm) ----左房 LA<35 , 左室 LV<55, 升主动脉 AO<35 ,主肺动脉 PA<30,右房 RA40×35 ,右室<25 左室流出道 18-40 ,右室流出道 18-35 厚度(mm) 室间隔IVS <12, 左室后壁LVPW <12,右室壁 <3-4,左室壁 <9-12 瓣口面积

JACC:对无症状严重主动脉瓣狭窄患者,换瓣术优于保守治疗

对于无症状的严重的主动脉瓣狭窄 (AS)患者,目前的指南建议,观察随访直到症状出现才行主动脉瓣置换术 (AVR) 。研究者对无症状的严重AS患者进行了一项研究,探究一经诊断就行AVR治疗和保守策略两种方案对患者的长期影响。该研究在2003年1月-2011年12月间,从多中心注册库纳入了3815名严重AS患者(主峰喷射速度>4.0 m/s,或平均主动脉压力梯度>40 mmHg,或主动脉瓣

Circ Cardiovasc Interv :经导管主动脉瓣植入术对二尖瓣关闭不全患者预后影响

瑞士伯尔尼大学医院,心内科Crochan J. O’Sullivan博士等人,研究了二尖瓣关闭不全与高危患者行经导管主动脉瓣植入术预后结局之间的关联,并将经导管主动脉瓣植入术治疗组与药物治疗组进行预后分析,认为二尖瓣关闭不全是经导管主动脉瓣植入术预后的独立预测因子,而且,在二尖瓣关闭不全患者中,药物治疗组的疗效不如经导管主动脉瓣植入术组,其研究成果发表在2月份Circulation Cardiov

JACC:主动脉瓣置换术可降低保守LEVF和低梯度的主动脉瓣狭窄患者的死亡率

低平均跨瓣压力梯度(<40mm Hg)和主动脉瓣面积小(<1.0cm2)的患者并患有主动脉瓣狭窄(AS)和保守左室射血分数引起了人们对主动脉瓣置换术(AVR)的狭窄和生存利益的实际严重程度的不确定性。这项研究分析了AVR对低梯度(LG)AS和保守左室射血分数患者死亡率和存活率的影响,包括反常的低流量(即每搏输出量指数<35ml/m2),低梯度(LF-LG)和正常流量,低梯度(NF

TCT 2014:主动脉瓣狭窄患者TAVR获益明显(PARTNER I 试验)

TCT2014会议上公布了最新的PARTNER I研究5年的随访结果,数据显示,对于主动脉瓣严重狭窄的高危患者,若不适宜行外科手术,经导管主动脉瓣置换术(TAVR) 比常规治疗更能使其长期获益。 来自克利夫兰诊所的Samir Kapadia医学博士对358例不适宜行外科手术的主动脉瓣狭窄患者进行了临床研究,将其随机分为使用Saplen瓣膜(Edwards Lifesciences)的TA

JACC:重度主动脉瓣狭窄患者的介入治疗与主动脉瓣置换术

    背景  经导管主动脉瓣置换术(TAVR)是在一定的高风险手术的严重主动脉瓣狭窄患者的一个选择。但并不知道是否可以将TAVR安全地引入到低风险患者。    意义  在NOTION(北欧主动脉瓣膜干预试验)随机临床试验中,比较所有研究队列的患者接受主动脉瓣置换手术(SAVR)和TAVR的区别。    方法 &nbs